Cardiovascular Preclinical Deal Benchmarks — US Only (2026)
Median upfront of $28M with total deal values reaching $591M in US Only territory.
Median Upfront
$28M
Total Deal Value
$381M
Royalty Range
3.7%–7.4%
Territory Multiplier
0.55x
Understanding Cardiovascular Deal Benchmarks at Preclinical
Preclinical Cardiovascular licensing deals in US Only territory command a median upfront payment of $28M, with values ranging from $10M at the low end to $49M for premium assets. These benchmarks reflect the risk-adjusted value of clinical-stage assets in the cardiovascular therapeutic area, where development costs, competitive dynamics, and market potential all factor into deal pricing.
Total deal values — including milestones for development, regulatory, and commercial achievements — range from $171M to $591M, with a median of $381M. Royalty rates for cardiovascular assets at this stage typically fall between 3.7% and 7.4% of net sales, reflecting the balance between licensor value contribution and licensee commercialization investment.
The US Only territory applies a 0.55x multiplier to base deal economics. This accounts for market size, regulatory complexity, pricing environment, and competitive landscape differences across geographies. Licensors negotiating us only rights should calibrate upfront expectations and milestone structures accordingly.
Full Market Analysis
Detailed deal economics, territory impact analysis, and royalty structure breakdown.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Full Benchmark Data
| Metric | Low | Median | High |
|---|---|---|---|
| Upfront Payment | $10M | $28M | $49M |
| Total Deal Value | $171M | $381M | $591M |
| Royalty Rate | 3.7% | — | 7.4% |
Comparable Deals
No territory-specific comparable deals. Use the calculator for full analysis.
See All Comparable Deals
View 0 comparable Cardiovascular transactions with upfront payments, total values, and deal structures.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Frequently Asked Questions
What is the average upfront payment for Preclinical Cardiovascular deals in US Only territory?
How does US Only territory affect Cardiovascular deal value?
What royalty rates are typical for Preclinical Cardiovascular licensing?
More Expert Insights
Royalty negotiation strategies and deal structure guidance.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Related Benchmarks
$72M upfront
Cardiovascular · Phase 1 · US Only
$278M upfront
Cardiovascular · Phase 2 · US Only
$759M upfront
Cardiovascular · Phase 3 · US Only
$2.1B upfront
Cardiovascular · Approved · US Only
$18M upfront
Oncology · Preclinical · US Only
$18M upfront
Neurology/CNS · Preclinical · US Only
$39M upfront
Immunology · Preclinical · US Only
$43M upfront
Metabolic/Obesity · Preclinical · US Only
Run Your Own Benchmark
These benchmarks are starting points. Get a customized valuation for your specific asset, indication, and deal structure.
Open SolidusCite This Data
Ambrosia Ventures. (2026). Cardiovascular Preclinical Deal Benchmarks — US Only (2026). Retrieved from https://solidus.ambrosiaventures.co/data/cardiovascular-preclinical-deals-us
<a href="https://solidus.ambrosiaventures.co/data/cardiovascular-preclinical-deals-us">Cardiovascular Preclinical Deal Benchmarks — US Only (2026)</a> — Ambrosia Ventures (2026)
<iframe src="https://solidus.ambrosiaventures.co/api/embed/chart?type=phase-upfront&ta=cardiovascular&theme=light" width="600" height="400" frameborder="0" style="border:1px solid #e2e8f0;border-radius:12px;"></iframe>
Data sourced from 1,600+ verified biopharma transactions. Updated monthly.